News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
620,287 Results
Type
Article (53077)
Company Profile (144)
Press Release (567053)
Multimedia
Podcasts (151)
Webinars (27)
Section
Business (160535)
Career Advice (2851)
Deals (30170)
Drug Delivery (156)
Drug Development (70328)
Employer Resources (174)
FDA (15436)
Job Trends (14144)
News (285762)
Policy (31024)
Tag
2027 Bio NC Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (2803)
Academic (2)
Accelerated approval (49)
Adcomms (35)
Allergies (162)
Alliances (42180)
ALS (221)
Alzheimer's disease (1790)
Antibody-drug conjugate (ADC) (419)
Approvals (15727)
Artificial intelligence (699)
Autoimmune disease (284)
Automation (56)
Bankruptcy (302)
Best Places to Work (10730)
BIOSECURE Act (22)
Biosimilars (228)
Biotechnology (92)
Bladder cancer (194)
Brain cancer (77)
Breast cancer (729)
Cancer (5671)
Cardiovascular disease (499)
Career advice (2414)
Career pathing (48)
CAR-T (322)
CDC (74)
Celiac Disease (3)
Cell therapy (874)
Cervical cancer (46)
Clinical research (61539)
Collaboration (1947)
Company closure (7)
Compensation (589)
Complete response letters (95)
COVID-19 (2817)
CRISPR (107)
C-suite (1070)
Cystic fibrosis (141)
Data (7473)
Decentralized trials (3)
Denatured (26)
Depression (171)
Dermatology (83)
Diabetes (567)
Diagnostics (6862)
Digital health (51)
Diversity (9)
Diversity, equity & inclusion (42)
Drug discovery (319)
Drug pricing (238)
Drug shortages (36)
Duchenne muscular dystrophy (290)
Earnings (62885)
Editorial (75)
Employer branding (18)
Employer resources (149)
Events (84886)
Executive appointments (1019)
FDA (18966)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1663)
Gene editing (230)
Generative AI (62)
Gene therapy (753)
GLP-1 (1141)
Government (4814)
Grass and pollen (6)
Guidances (399)
Healthcare (17234)
HIV (83)
Huntington's disease (55)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (95)
Immunology and inflammation (312)
Immuno-oncology (95)
Indications (180)
Infectious disease (3168)
Inflammatory bowel disease (205)
Inflation Reduction Act (14)
Influenza (135)
Intellectual property (267)
Interviews (544)
IPO (14312)
IRA (55)
Job creations (3656)
Job search strategy (1987)
JPM (71)
Kidney cancer (20)
Labor market (105)
Layoffs (656)
Leadership (49)
Legal (8223)
Liver cancer (90)
Longevity (32)
Lung cancer (753)
Lymphoma (423)
Machine learning (61)
Management (59)
Manufacturing (1038)
MASH (188)
Medical device (12524)
Medtech (12636)
Mergers & acquisitions (17048)
Metabolic disorders (1523)
mRNA (220)
Multiple sclerosis (181)
NASH (21)
Neurodegenerative disease (439)
Neuropsychiatric disorders (118)
Neuroscience (3306)
Neurotech (1)
NextGen: Class of 2026 (6174)
Non-profit (4619)
Now hiring (57)
Obesity (742)
Opinion (353)
Ovarian cancer (216)
Pain (256)
Pancreatic cancer (297)
Parkinson's disease (346)
Partnered (34)
Patents (575)
Patient recruitment (636)
Peanut (56)
People (50775)
Pharmaceutical (33)
Pharmacy benefit managers (33)
Phase 1 (18481)
Phase 2 (26913)
Phase 3 (21377)
Pipeline (8494)
Policy (370)
Postmarket research (2234)
Preclinical (7437)
Press Release (69)
Prostate cancer (289)
Psychedelics (66)
Radiopharmaceuticals (285)
Rare diseases (1090)
Real estate (5817)
Recruiting (68)
Regulatory (23285)
Reports (53)
Research institute (2608)
Resumes & cover letters (449)
Rett syndrome (38)
RNA editing (20)
RSV (90)
Schizophrenia (182)
Series A (274)
Series B (199)
Service/supplier (7)
Sickle cell disease (104)
Special edition (31)
Spinal muscular atrophy (170)
Sponsored (49)
Startups (3488)
State (2)
Stomach cancer (18)
Supply chain (125)
Tariffs (99)
The Weekly (122)
Vaccines (1147)
Venture capital (116)
Weight loss (522)
Women's health (126)
Worklife (22)
Date
Today (80)
Last 7 days (606)
Last 30 days (3198)
Last 365 days (27133)
2026 (11636)
2025 (27115)
2024 (31286)
2023 (35305)
2022 (45806)
2021 (49878)
2020 (48641)
2019 (42989)
2018 (32701)
2017 (29566)
2016 (28541)
2015 (32820)
2014 (25947)
2013 (22861)
2012 (22222)
2011 (22784)
2010 (19995)
Location
Africa (886)
Alabama (89)
Alaska (5)
Arizona (262)
Arkansas (15)
Asia (37983)
Australia (6617)
California (11133)
Canada (3454)
China (1254)
Colorado (510)
Connecticut (512)
Delaware (352)
Europe (86331)
Florida (1838)
Georgia (386)
Hawaii (2)
Idaho (59)
Illinois (996)
India (84)
Indiana (552)
Iowa (21)
Japan (512)
Kansas (117)
Kentucky (44)
Louisiana (45)
Maine (82)
Maryland (1352)
Massachusetts (7561)
Michigan (338)
Minnesota (564)
Mississippi (7)
Missouri (143)
Montana (32)
Nebraska (26)
Nevada (133)
New Hampshire (83)
New Jersey (3277)
New Mexico (29)
New York (3144)
North Carolina (1533)
North Dakota (10)
Northern California (5545)
Ohio (394)
Oklahoma (18)
Oregon (38)
Pennsylvania (2345)
Puerto Rico (27)
Rhode Island (45)
South America (1246)
South Carolina (80)
South Dakota (1)
Southern California (4357)
Tennessee (184)
Texas (1886)
United States (40526)
Utah (396)
Vermont (1)
Virginia (304)
Washington D.C. (70)
Washington State (941)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
620,287 Results for "la jolla institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
La Jolla Labs, Inc. Announces First Patient Treated with Custom Antisense Therapy GBFsen for familial ALS
April 30, 2026
·
1 min read
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology agreed to start a research collaboration to create antigens for the next-generation vaccines to deliver innovative solutions to unmet medical need in infectious diseases.
April 18, 2024
·
2 min read
Job Trends
The Next Cambridge? LA Sets Its Sights Higher
The Los Angeles region is one of California’s fastest-growing life sciences hubs, according to a California Life Sciences sector report. The CEO of BioscienceLA discusses the market’s strengths, challenges and where it might be five years from now.
March 12, 2026
·
5 min read
·
Angela Gabriel
Press Releases
ImPact Biotech Presents Preliminary Data from Phase 1 Study of Padeliporfin VTP in LA-PDAC at SIR 2026 and Provides Strategic Business Update
April 14, 2026
·
6 min read
Press Releases
SK pharmteco Announces Successful FDA Inspection of Small Molecule Manufacturing Facility in La Porte, Texas
March 17, 2026
·
2 min read
Press Releases
NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
March 25, 2026
·
8 min read
Deals
Innoviva to Acquire La Jolla Pharmaceutical Company
Innoviva, Inc. and La Jolla Pharmaceutical Company announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla.
July 11, 2022
·
10 min read
XNK presents at the 8th Innate Killer Summit in La Jolla, San Diego
XNK Therapeutics AB announced its extensive participation at the 8th Annual Innate Killer Summit in La Jolla, San Diego, CA, March 28-30.
March 22, 2023
·
2 min read
Press Releases
Medical Care Technologies Inc. (OTC Pink:MDCE) Announces Attendance at CES 2026 in Las Vegas
January 7, 2026
·
2 min read
Business
La Jolla Institute for Immunology Acquires the Carterra LSA Platform to Advance State-of-the-Art Immunological and Infectious Disease Research
Carterra, Inc. and La Jolla Institute for Immunology (LJI) announced today that LJI has acquired a Carterra LSA instrument to enhance its antibody screening and characterization work.
August 1, 2022
·
5 min read
1 of 62,029
Next
